Recurrence	Recurrence	NN	B-NP	O	
of	of	IN	B-PP	O	
Helicobacter pylori	Helicobacter_pylori	NNP	B-NP	O	
infection	infection	NN	I-NP	O	
1	1	CD	I-NP	O	
year	year	NN	I-NP	O	
after	after	IN	B-PP	O	
successful	successful	JJ	B-NP	O	
treatment	treatment	NN	I-NP	O	
:	:	:	O	O	
prospective	prospective	JJ	B-NP	O	
cohort	cohort	JJ	I-NP	O	
study	study	NN	I-NP	O	
in	in	IN	B-PP	O	
the	the	DT	B-NP	O	
Republic	Republic	NNP	I-NP	O	
of	of	IN	B-PP	O	
Yemen	Yemen	NNP	B-NP	O	
.	.	.	O	O	

To	To	TO	B-VP	O	
investigate	investigate	VB	I-VP	O	
the	the	DT	B-NP	O	
prevalence	prevalence	NN	I-NP	O	
of	of	IN	B-PP	O	
Helicobacter pylori	Helicobacter_pylori	NNP	B-NP	O	
infection	infection	NN	I-NP	O	
in	in	IN	B-PP	O	
dyspeptic	dyspeptic	JJ	B-NP	O	
patients	patient	NNS	I-NP	O	
in	in	IN	B-PP	O	
the	the	DT	B-NP	O	
Republic	Republic	NNP	I-NP	O	
of	of	IN	B-PP	O	
Yemen	Yemen	NNP	B-NP	O	
and	and	CC	O	O	
the	the	DT	B-NP	O	
recurrence	recurrence	NN	I-NP	O	
rate	rate	NN	I-NP	O	
1	1	CD	I-NP	O	
year	year	NN	I-NP	O	
after	after	IN	B-PP	O	
apparently	apparently	RB	B-NP	O	
successful	successful	JJ	I-NP	O	
eradication	eradication	NN	I-NP	O	
.	.	.	O	O	

A	A	DT	B-NP	O	
total	total	NN	I-NP	O	
of	of	IN	B-PP	O	
275	275	CD	B-NP	O	
patients	patient	NNS	I-NP	O	
with	with	IN	B-PP	O	
chronic	chronic	JJ	B-NP	O	
dyspepsia	dyspepsia	NN	I-NP	O	
seen	see	VBN	B-VP	O	
in	in	IN	B-PP	O	
one	one	CD	B-NP	O	
clinic	clinic	NN	I-NP	O	
were	be	VBD	B-VP	O	
enrolled	enrol	VBN	I-VP	O	
.	.	.	O	O	

Gastric	Gastric	JJ	B-NP	O	
biopsies	biopsy	NNS	I-NP	O	
were	be	VBD	B-VP	O	
obtained	obtain	VBN	I-VP	O	
at	at	IN	B-PP	O	
endoscopy	endoscopy	NN	B-NP	O	
and	and	CC	I-NP	O	
H. pylori	H._pylori	NN	I-NP	O	
infection	infection	NN	I-NP	O	
was	be	VBD	B-VP	O	
diagnosed	diagnose	VBN	I-VP	O	
using	use	VBG	B-VP	O	
the	the	DT	B-NP	O	
rapid	rapid	JJ	I-NP	O	
urease	urease	NN	I-NP	O	
test	test	NN	I-NP	O	
.	.	.	O	O	

Patients	Patient	NNS	B-NP	O	
with	with	IN	B-PP	O	
H. pylori	H._pylori	NN	B-NP	O	
infection	infection	NN	I-NP	O	
were	be	VBD	B-VP	O	
given	give	VBN	I-VP	O	
either	either	CC	O	O	
clarithromycin	clarithromycin	NN	B-NP	O	
or	or	CC	I-NP	O	
metronidazole	metronidazole	NN	I-NP	O	
-	-	HYPH	B-VP	O	
based	base	VBN	B-NP	O	
triple	triple	JJ	I-NP	O	
therapy	therapy	NN	I-NP	O	
.	.	.	O	O	

Six	Six	CD	B-NP	O	
weeks	week	NNS	I-NP	O	
later	later	RB	B-ADVP	O	
H. pylori	H._pylori	NNP	B-NP	O	
status	status	NN	I-NP	O	
was	be	VBD	B-VP	O	
assessed	assess	VBN	I-VP	O	
using	use	VBG	B-VP	O	
the	the	DT	B-NP	O	
C-urea	C-urea	NN	I-NP	O	
breath	breath	NN	I-NP	O	
test	test	NN	I-NP	O	
(	(	(	O	O	
C-UBT	C-UBT	NN	B-NP	O	
)	)	)	O	O	
.	.	.	O	O	

Those	Those	DT	B-NP	O	
who	who	WP	B-NP	O	
were	be	VBD	B-VP	O	
negative	negative	JJ	B-ADJP	O	
for	for	IN	B-SBAR	O	
H. pylori	H._pylori	NNP	B-NP	O	
had	have	VBD	B-VP	O	
a	a	DT	B-NP	O	
further	further	JJ	I-NP	O	
C-UBT	C-UBT	NN	I-NP	O	
after	after	IN	B-PP	O	
1	1	CD	B-NP	O	
year	year	NN	I-NP	O	
to	to	TO	B-VP	O	
establish	establish	VB	I-VP	O	
the	the	DT	B-NP	O	
recurrence	recurrence	NN	I-NP	O	
rate	rate	NN	I-NP	O	
.	.	.	O	O	

The	The	DT	B-NP	O	
prevalence	prevalence	NN	I-NP	O	
of	of	IN	B-PP	O	
H. pylori	H._pylori	NN	B-NP	O	
infection	infection	NN	I-NP	O	
at	at	IN	B-PP	O	
entry	entry	NN	B-NP	O	
to	to	TO	B-PP	O	
the	the	DT	B-NP	O	
study	study	NN	I-NP	O	
was	be	VBD	B-VP	O	
82.2	82.2	CD	B-NP	O	
%	%	NN	I-NP	O	
[	[	(	O	O	
95%	95%	CD	B-NP	O	
confidence	confidence	NN	I-NP	O	
interval	interval	NN	I-NP	O	
(	(	(	O	O	
CI	CI	NN	B-NP	O	
)	)	)	O	O	
78-87	78-87	CD	B-NP	O	
%	%	NN	I-NP	O	
]	]	)	O	O	
.	.	.	O	O	

The	The	DT	B-NP	O	
overall	overall	JJ	I-NP	O	
eradication	eradication	NN	I-NP	O	
rate	rate	NN	I-NP	O	
6	6	CD	B-NP	O	
weeks	week	NNS	I-NP	O	
after	after	IN	B-SBAR	O	
treatment	treatment	NN	B-NP	O	
was	be	VBD	B-VP	O	
49.1	49.1	CD	B-NP	O	
%	%	NN	I-NP	O	
(	(	(	O	O	
95%	95%	CD	B-NP	O	
CI	CI	NN	I-NP	O	
42.6-55.6	42.6-55.6	CD	B-NP	O	
%	%	NN	I-NP	O	
)	)	)	O	O	
by	by	IN	B-PP	O	
intention-to	intention-to	AFX	B-NP	B-protein	
-	-	HYPH	I-NP	O	
treat	treat	NN	I-NP	O	
analysis	analysis	NN	I-NP	O	
,	,	,	O	O	
and	and	CC	O	O	
60%	60%	CD	B-NP	O	
(	(	(	O	O	
95%	95%	CD	B-NP	O	
CI	CI	NN	I-NP	O	
53-67	53-67	CD	B-NP	O	
%	%	NN	I-NP	O	
)	)	)	O	O	
by	by	IN	B-PP	O	
per-protocol	per-protocol	JJ	B-NP	O	
analysis	analysis	NN	I-NP	O	
.	.	.	O	O	

Recurrence	Recurrence	NN	B-NP	O	
rate	rate	NN	I-NP	O	
of	of	IN	B-PP	O	
H. pylori	H._pylori	NN	B-NP	O	
infection	infection	NN	I-NP	O	
at	at	IN	B-PP	O	
1	1	CD	B-NP	O	
year	year	NN	I-NP	O	
was	be	VBD	B-VP	O	
34%	34%	CD	B-NP	O	
(	(	(	O	O	
95%	95%	CD	B-NP	O	
CI	CI	NN	I-NP	O	
14-45	14-45	CD	B-NP	O	
%	%	NN	I-NP	O	
)	)	)	O	O	
and	and	CC	O	O	
the	the	DT	B-NP	O	
only	only	JJ	I-NP	O	
predictor	predictor	NN	I-NP	O	
of	of	IN	B-PP	O	
recurrence	recurrence	NN	B-NP	O	
was	be	VBD	B-VP	O	
an	an	DT	B-NP	O	
excess	excess	JJ	I-NP	O	
delta	delta	NN	I-NP	O	
C-UBT	C-UBT	NN	I-NP	O	
value	value	NN	I-NP	O	
less	less	JJR	B-ADJP	O	
than	than	IN	B-PP	O	
3.5	3.5	CD	B-NP	O	
per	per	IN	B-PP	O	
million	million	CD	B-NP	O	
but	but	CC	O	O	
equal	equal	JJ	B-ADJP	O	
to	to	TO	B-PP	O	
or	or	CC	O	O	
greater	great	JJR	B-ADJP	O	
than	than	IN	B-PP	O	
2.5	2.5	CD	B-NP	O	
per	per	IN	B-PP	O	
million	million	CD	B-NP	O	
at	at	IN	B-PP	O	
6	6	CD	B-NP	O	
weeks	week	NNS	I-NP	O	
after	after	IN	B-PP	O	
treatment	treatment	NN	B-NP	O	
(	(	(	O	O	
odds	odd	NNS	B-NP	O	
ratio	ratio	NN	B-NP	O	
2.28	2.28	CD	I-NP	O	
;	;	:	O	O	
95%	95%	CD	B-NP	O	
CI	CI	NN	I-NP	O	
1.17-4.44	1.17-4.44	CD	B-NP	O	
;	;	:	O	O	
P	P	NN	B-NP	O	
=	=	SYM	B-VP	O	
0.028	0.028	CD	B-NP	O	
)	)	)	O	O	
.	.	.	O	O	

The	The	DT	B-NP	O	
prevalence	prevalence	NN	I-NP	O	
of	of	IN	B-PP	O	
H. pylori	H._pylori	NN	B-NP	O	
infection	infection	NN	I-NP	O	
in	in	IN	B-PP	O	
dyspeptic	dyspeptic	JJ	B-NP	O	
patients	patient	NNS	I-NP	O	
in	in	IN	B-PP	O	
Yemen	Yemen	NN	B-NP	O	
is	be	VBZ	B-VP	O	
very	very	RB	B-ADJP	O	
high	high	JJ	I-ADJP	O	
,	,	,	O	O	
the	the	DT	B-NP	O	
eradication	eradication	NN	I-NP	O	
rate	rate	NN	I-NP	O	
with	with	IN	B-PP	O	
standard	standard	JJ	B-NP	O	
triple	triple	JJ	I-NP	O	
therapy	therapy	NN	I-NP	O	
was	be	VBD	B-VP	O	
unsatisfactory	unsatisfactory	JJ	B-ADJP	O	
probably	probably	RB	B-ADVP	O	
because	because	IN	B-PP	O	
of	of	IN	I-PP	O	
widespread	widespread	JJ	B-NP	O	
bacterial	bacterial	JJ	I-NP	O	
resistance	resistance	NN	I-NP	O	
due	due	JJ	B-PP	O	
to	to	TO	B-PP	O	
unrestricted	unrestricted	JJ	B-NP	O	
antibiotic	antibiotic	JJ	I-NP	O	
use	use	NN	I-NP	O	
.	.	.	O	O	

The	The	DT	B-NP	O	
recurrence	recurrence	NN	I-NP	O	
rate	rate	NN	I-NP	O	
of	of	IN	B-PP	O	
infection	infection	NN	B-NP	O	
at	at	IN	B-PP	O	
1	1	CD	B-NP	O	
year	year	NN	I-NP	O	
was	be	VBD	B-VP	O	
high	high	JJ	B-ADJP	O	
,	,	,	O	O	
as	as	IN	B-PP	O	
a	a	DT	B-NP	O	
result	result	NN	I-NP	O	
of	of	IN	B-PP	O	
recrudescence	recrudescence	NN	B-NP	O	
of	of	IN	B-PP	O	
incompletely	incompletely	RB	B-NP	O	
eradicated	eradicate	VBN	I-NP	O	
organisms	organism	NNS	I-NP	O	
rather	rather	RB	B-PP	O	
than	than	IN	I-PP	O	
reinfection	reinfection	NN	B-NP	O	
.	.	.	O	O	

